We detected low-level CD9 expression in primary neuroblastomas that correlated with metastasized high-risk disease, low probability of patient survival and established clinical and molecular markers for unfavorable disease including MYCN amplification in the tumor. This evidence concerns the gene CD9 and neuroblastoma.